Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Denali Therapeutics's DNL-343?
DNL-343 is a small molecule commercialized by Denali Therapeutics, with a leading Phase III program in Amyotrophic Lateral Sclerosis. According...
Data Insights
DNL-343 by Denali Therapeutics for Amyotrophic Lateral Sclerosis: Likelihood of Approval
DNL-343 is under clinical development by Denali Therapeutics and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData,...